Press monitoring
COMP recommends that Alprolix® maintains orphan designation for treatment of haemophilia B
11.4.2016 | Press monitoring
Swedish Orphan Biovitrum AB (publ) (Sobi(TM)) (STO:SOBI) and collaboration partner Biogen have received a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) recommending the European Commission (EC) to maintain the orphan designation for Alprolix® (eftrenonacog alfa), a recombinant...
Typhoid toxin increases host survival and promotes asymptomatic infection
11.4.2016 | Press monitoring
DNA damage caused by bacterial genotoxins has been linked to cancer, but what, if any, function genotoxins have in the context of a natural infection is not clear. Teresa Frisan, from the Karolinska Institute in Stockholm, Sweden, and colleagues focused on the typhoid toxin from Salmonella enterica Typhi (S. Typhi), and specifically looked at...
Simplified Magnetogenetics
8.4.2016 | Press monitoring
A new technique allows researchers to rapidly and reversibly activate neurons with a magnetically sensitive protein. Fusing a channel protein found in nerve endings with the magnetically sensitive region of an iron-storing protein called ferritin, Ali Güler of the University of Virginia and colleagues have devised a simpler way to selectively...
Could 3D-printed ovaries help treat infertility?
6.4.2016 | Press monitoring
The rise of 3D printing has facilitated some impressive feats in the medical world, helping to create everything from a new upper jaw for a cancer patient to a titanium sternum and rib cage. Now, a team from Northwestern University in Boston has used the technology to produce a prosthetic ovary, which was successfully implanted into mice,...
One crop breeding cycle from starvation
4.4.2016 | Press monitoring
In the race against world hunger, we're running out of time. By 2050, the global population will have grown and urbanized so much that we will need to produce 87 percent more of the four primary food crops - rice, wheat, soy, and maize - than we do today. At the same time, the climate is projected to change over the next 30 years, with warmer...
Bio coding language makes it easier to hack living cells
1.4.2016 | Press monitoring
Tinkering with life just got easier. A tool that lets you design DNA circuits using a simple symbolic language makes programming living cells as straightforward as writing code for computers. The tool uses an existing language called Verilog, which is used by chip designers to design electronic circuits. The idea is to make programming cells more...
Aegerion Pharmaceuticals Observes World Lipodystrophy Day
31.3.2016 | Press monitoring
CAMBRIDGE, Mass., March 31, 2016 (GLOBE NEWSWIRE) - Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating rare diseases, announced today its observance of World Lipodystrophy Day.
Medtronic Launches Percutaneous Tibial Neuromodulation Delivered by the NURO System for the Treatment of Overactive Bladder (OAB)
30.3.2016 | Press monitoring
New Medtronic Treatment Targets Underlying Bladder and Brain Miscommunication and Could Bring Desperately Needed Relief to Tens of Millions Struggling with OAB. DUBLIN - March 30, 2016 - Medtronic plc (NYSE: MDT) today announced the launch of its NURO(TM) System that delivers percutaneous tibial neuromodulation (PTNM) for the treatment of...
Wounds may be treated using ... frog foam?
30.3.2016 | Press monitoring
When the tiny Tungara frog lays its eggs, it also secretes a protein cocktail that it beats into a foam using its back legs. Surrounding the eggs, that foam protects them from predators, germs and environmental stress. As it turns out, a synthetic version of the substance may also one day have another use – delivering medication to serious skin...
Herantis Pharma receives orphan designation of CDNF for treatment of ALS
29.3.2016 | Press monitoring
The European Medicines Agency's Committee for Orphan Medicinal Products (COMP) has issued a positive opinion on the application of Herantis Pharma Plc ("Herantis") for orphan drug designation of recombinant human Cerebral Dopamine Neurotrophic Factor (CDNF) for treatment of amyotrophic lateral sclerosis (ALS).
